ACM
CTMX icon

ADAR1 Capital Management’s CytomX Therapeutics CTMX Stock Holding History

ADAR1 Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100,000
Closed -$426K – 316
2025
Q4 		$426K Buy
+100,000
New +$380K 0.03% 196

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

ADAR1 Capital Management's CTMX Position: Q2 2026 in Review

ADAR1 Capital Management reduced its CytomX Therapeutics (CTMX) stake by 1.3% in Q2 2026, selling an estimated $172K and leaving 3,365,118 shares worth $12.6M. The position accounts for 0.58% of the portfolio, ranked #43.

ADAR1 Capital Management first reported a position in CTMX in Q1 2024 and has held it in 10 quarters since. The position peaked at $17.8M in Q4 2025. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • ADAR1 Capital Management held 3,365,118 shares of CytomX Therapeutics worth $12.6M as of Q2 2026.
  • ADAR1 Capital Management sold 45,072 CytomX Therapeutics shares in Q2 2026, an estimated $172K.
  • CytomX Therapeutics made up 0.58% of ADAR1 Capital Management's portfolio in Q2 2026, its #43 holding.
  • ADAR1 Capital Management first reported a position in CytomX Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • ADAR1 Capital Management's CytomX Therapeutics position peaked at $17.8M in Q4 2025.
  • 178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.